InvestorsHub Logo
Followers 9
Posts 710
Boards Moderated 0
Alias Born 12/13/2004

Re: bowonwing post# 1176

Sunday, 07/06/2008 1:17:12 PM

Sunday, July 06, 2008 1:17:12 PM

Post# of 2070
Bow,

I was concerned also. The board approved Walbert’s dual roll, apparently with no dissent. I got this impression during the SHM. I also got the impression, with no uncertain terms expressed at the SHM, that the IDMI is all but sold – I do not believe that the final value of the sale depends on approval of L-MPT-PE by the EMEA. The announcement of the sale may well happen prior to the EMEA approval. One of the directors did agree with me when I stated that the real value of such a deal would be IDM-2101. Think about it. L-MPT-PE is small potatoes for a BP or large biotech - it is the pipeline where the value of IDMI lies.

Walbert’s new CEO position would not have been approved if the board thought that IDMI would be going into the actual marketing of L-MPT-PE. If that were the case, Walbert would have resigned for the new position.